Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David Allen Reardon, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. P50CA108786 (BIGNER, DARELL D) Jul 1, 2004 - Aug 31, 2010
    NIH/NCI
    SPORE in Brain Cancer
    Role: Co-Principal Investigator
  2. R21CA105781 (REARDON, DAVID A) Sep 29, 2003 - Aug 31, 2006
    NIH/NCI
    Phase II Study of 44Gy from 131I-81C6 for CNS Tumors
    Role: Principal Investigator
  3. P20CA096890 (BIGNER, DARELL D) Sep 30, 2002 - Aug 31, 2004
    NIH/NCI
    SPORE in Brain Cancer
    Role: Co-Principal Investigator
  4. P50NS020023 (BIGNER, DARELL D) Apr 1, 1984 - Jan 31, 2014
    NIH/NINDS
    SRC on Primary Tumors of the CNS
    Role: Co-Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 Feb 04; JCO1801207. PMID: 30715997.
    Citations:    
  2. Iorgulescu JB, Torre M, Harary M, Smith TR, Aizer AA, Reardon DA, Barnholtz-Sloan JS, Perry A. The Misclassification of Diffuse Gliomas: Rates and Outcomes. Clin Cancer Res. 2019 Jan 11. PMID: 30635340.
    Citations:    Fields:    
  3. Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Ansell PJ, Bain E, Holen KD, Maag D, Merrell R. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. Neuro Oncol. 2019 Jan 01; 21(1):106-114. PMID: 29982805.
    Citations: 1     Fields:    
  4. Huang RY, Bi WL, Weller M, Kaley T, Blakeley J, Dunn I, Galanis E, Preusser M, McDermott M, Rogers L, Raizer J, Schiff D, Soffietti R, Tonn JC, Vogelbaum M, Weber D, Reardon DA, Wen PY. Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neuro Oncol. 2019 Jan 01; 21(1):26-36. PMID: 30137421.
    Citations:    Fields:    
  5. Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, Shukla SA, Hu Z, Li L, Le PM, Allesøe RL, Richman AR, Kowalczyk MS, Abdelrahman S, Geduldig JE, Charbonneau S, Pelton K, Iorgulescu JB, Elagina L, Zhang W, Olive O, McCluskey C, Olsen LR, Stevens J, Lane WJ, Salazar AM, Daley H, Wen PY, Chiocca EA, Harden M, Lennon NJ, Gabriel S, Getz G, Lander ES, Regev A, Ritz J, Neuberg D, Rodig SJ, Ligon KL, Suvà ML, Wucherpfennig KW, Hacohen N, Fritsch EF, Livak KJ, Ott PA, Wu CJ, Reardon DA. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019 01; 565(7738):234-239. PMID: 30568305.
    Citations:    Fields:    
  6. Reardon DA, Weller M. Pseudoprogression: fact or wishful thinking in neuro-oncology? Lancet Oncol. 2018 Dec; 19(12):1561-1563. PMID: 30507413.
    Citations:    Fields:    
  7. George E, Kijewski MF, Dubey S, Belanger AP, Reardon DA, Wen PY, Kesari S, Horky L, Park MA, Huang RY. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy. AJR Am J Roentgenol. 2018 Dec; 211(6):1342-1347. PMID: 30332289.
    Citations:    Fields:    
  8. Passaro C, Alayo Q, De Laura I, McNulty J, Grauwet K, Ito H, Bhaskaran V, Mineo M, Lawler SE, Shah K, Speranza MC, Goins W, McLaughlin E, Fernandez S, Reardon DA, Freeman GJ, Chiocca EA, Nakashima H. Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy. Clin Cancer Res. 2019 Jan 01; 25(1):290-299. PMID: 30279232.
    Citations:    Fields:    
  9. Ellingson BM, Aftab DT, Schwab GM, Hessel C, Harris RJ, Woodworth DC, Leu K, Chakhoyan A, Raymond C, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Wen PY, Cloughesy TF. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Neuro Oncol. 2018 Sep 03; 20(10):1411-1418. PMID: 29660005.
    Citations:    Fields:    
  10. Kurz SC, Cabrera LP, Hastie D, Huang R, Unadkat P, Rinne M, Nayak L, Lee EQ, Reardon DA, Wen PY. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology. 2018 Oct 02; 91(14):e1355-e1359. PMID: 30171077.
    Citations:    Fields:    
  11. Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018 Aug 23; 379(8):722-730. PMID: 30134131.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  12. Zhou M, Zhou Y, Liao H, Rowland BC, Kong X, Arvold ND, Reardon DA, Wen PY, Lin AP, Huang RY. Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas. Neuro Oncol. 2018 Aug 02; 20(9):1262-1271. PMID: 29438510.
    Citations: 2     Fields:    
  13. Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 Aug 02; 20(9):1240-1250. PMID: 29660006.
    Citations: 1     Fields:    
  14. Iorgulescu JB, Reardon DA, Chiocca EA, Wu CJ. Immunotherapy for glioblastoma: going viral. Nat Med. 2018 Aug; 24(8):1094-1096. PMID: 30082860.